{
  "ticker": "ASPI",
  "content": "**Report Generated:** January 13, 2026  \n**Next Refresh:** April 14, 2026\n\n**Disclaimer:** This sell-side report was generated using Claude Sonnet 4 (claude-sonnet-4-20250514). Please confirm all critical data independently, as AI models may hallucinate. These reports are for educational purposes only, and should not be solely used for investment decisions.\n\n---\n\n# ASP Isotopes Inc. (ASPI) - Comprehensive Analysis Report\n\n## 1. Company Overview\n\nASP Isotopes Inc., a development stage advanced materials company, engages in the production, distribution, marketing, and sale of isotopes. It operates in two segments, Nuclear Fuels, and Specialist Isotopes and Related Services. The Nuclear Fuels segment focuses on the research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods used to separate high-value, low-volume isotopes, such as C-14, Mo-100 and Si-28, for target end markets, including pharmaceuticals and agrochemicals, nuclear medical imaging, and semiconductors; provision of related services; and operation of PET labs.\n\nThe company offers the Aerodynamic Separation Process (ASP) technology, which separates gas species and isotopes in a volatile state; and the Quantum Enrichment (QE) technology, which separates isotopes. It also produces and commercializes Molybdenum-100, Molybdenum-98, and Ytterbium-176 for the nuclear medical industry. In addition, the company develops Zinc-67/68, Nickel-64, and Xenon 129/136 for the nuclear medical industry; Lithium-7, Uranium-235, and Chlorine-37 for the energy industry; and Germanium-70/72/74 for semiconductor markets. ASP Isotopes Inc. was incorporated in 2021 and is based in Washington, District Of Columbia.\n\n## 2. Current Market Data\n\nThe current price of ASPI is 7.51 USD â€” it has increased by 16.61% in the past 24 hours. As of today, ASP Isotopes Inc(ASPI) shares are valued at $7.42. The company's market cap stands at 822.15M, with a P/E ratio of -5.27. The stock's 52-week range extends from a low of $3.65 to a high of $14.49.\n\n## 3. Existing Products/Services\n\n**Isotope Production Technologies:**\n- The Aerodynamic Separation Process utilizes gaseous diffusion via a stationary wall centrifuge paired with proprietary flow directors to separate isotopes of varying levels of atomic mass.\n- Quantum enrichment technology employs precisely tuned lasers and quantum mechanical principles to efficiently separate isotopes based on their unique transition energies, achieving high selectivity for most elements.\n\n**Currently Producing Isotopes:**\n- ASP Isotopes is transitioning from a development stage to a commercial stage isotope enrichment company, having already announced in 2025 that three of its enrichment plants are now commercially producing Carbon-14, Silicon-28 and Ytterbium-176.\n- ASP Isotopes (NASDAQ: ASPI) announced a supply contract for its largest quantity of enriched silicon-28 to date, with deliveries expected in Q1 2026, and the acquisition of an independent radiopharmacy in Florida, US to expand PET Labs' operations outside South Africa.\n\n## 4. Planned Products/Services/Projects\n\n**Quantum Leap Energy (QLE) Spinoff:**\n- ASP Isotopes Inc. (NASDAQ: ASPI) today announced that its wholly-owned subsidiary, Quantum Leap Energy LLC (\"QLE\"), has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the \"SEC\") relating to the proposed initial public offering of QLE's Class A common stock.\n- QLE has also filed S-1 documentation with the SEC, highlighting our commitment to the stated ASP Isotopes goals of spinning out QLE in quarter four 2025.\n\n**Nuclear Fuel Production:**\n- QLE has made progress on our MOU with Fermi and is providing requisite information to utilize the 11-gigawatt data center complex in Amarillo, Texas, as a location for uranium enrichment to produce LEU Plus and HALEU.\n- Thinking about our future and our expected company development roadmap, we intend to start our engineering design work in South Africa with our first demonstration plants to be operational there, focusing on lithium and uranium. Our plan is to have demonstration plants in the U.S.\n\n## 5. Growth Strategy\n\nThe Combination is expected to create a vertically and horizontally integrated supply chain potentially lowering isotope enrichment costs by 96% versus current cash costs. The goal of the combined group is to generate over $300 million in EBITDA in 2030, which is expected to be driven by a mix of isotopes, helium and LNG sales into the South African energy market, based on management's current estimates.\n\nASP is an advanced materials company dedicated to developing technology and processes designed to produce and enrich isotopes used in multiple markets, which include Nuclear Medicine and therapeutics, green energy generation, and quantum computing. Our initial focus is to utilize our proprietary ASP technology to construct, commission, and later produce commercial amounts of highly enriched isotopes for the Nuclear medicine market at our plants located in South Africa.\n\n## 6. Current and Potential Major Clients\n\n**TerraPower Partnership:**\n- ASP has secured major deals, including a 25-year contract worth $27 million annually for Molybdenum-100 and an MOU with TerraPower to supply HALEU for advanced nuclear reactors.\n- Progress has been made towards operation of the existing test batteries at Nexa Bellendawa to produce helium for TerraPower.\n\n**Major Supply Agreements:**\n- ASP Isotopes (NASDAQ: ASPI) announced a supply contract for its largest quantity of enriched silicon-28 to date, with deliveries expected in Q1 2026\n\n## 7. Financial Data & Performance\n\n**Recent Financial Results:**\n- Revenue for the first nine months of ... $96,512,193.\n- In 2024, ASP Isotopes's revenue was $4.14 million, an increase of 857.04% compared to the previous year's $433,026. Losses were -$35.11 million, 115.6% more than in 2023.\n\n**Cash Position:**\n- $110,000,000 from common stock issuance in the first nine months\n- ASP Isotopes (NASDAQ: ASPI) priced an underwritten public offering of 17,167,380 shares of common stock for gross proceeds of approximately $210.3 million, before underwriting discounts, commissions and offering expenses. The offering is expected to close on October 16, 2025, subject to customary closing conditions.\n\n## 8. Market Shares\n\nWhile specific market share percentages were not disclosed in the search results, Isotopes have one of the most severely compromised supply chains of any material in the world and the US Department of Energy and the majority of Western governments also identify isotopes as critical materials. For example, global demand for HALEU, used in advanced nuclear reactors, could reach 3,000 metric tons annually by 2030.\n\n## 9. Comparison to Competitors\n\nCompanies like SHINE Technologies and ASP Isotopes are actively working to establish Yb-176 enrichment capabilities outside of Russia, a move that is not just about cost but about insulating their operations from geopolitical shocks. Unlike competitors, ASP directly enriches silane gas for Silicon-28, creating a purer product for semiconductors and quantum computing\n\nCompetitors of ASP Isotopes include Infinium and 4 more. The company faces competition from established isotope producers and nuclear fuel suppliers globally.\n\n## 10. Partnerships, Mergers and Acquisitions\n\n**Renergen Acquisition (Closed January 7, 2026):**\n- ASP Isotopes announced it closed the acquisition of Renergen, forming a combined company focused on isotopes and liquid helium supply.\n- The combined company expects $750 million of debt funding: $500 million senior DFC facility and a $250 million Standard Bank facility. ASPI acquired Renergen's Virginia Gas project, which has recorded significant helium concentrations and prior $40 million DFC funding.\n- Renergen's key asset is the Virginia Gas project, where Helium concentrations are more than 10x the global average.\n\n**Executive Integration:**\n- In connection with the closing of the acquisition of Renergen, the Company's Compensation Committee approved inducement grants to two key employees of Renergen as a material inducement to employment with ASP Isotopes following its acquisition of Renergen. The Compensation Committee approved the grant to each of Stefano Marani (appointed as President, Electronics and Space) and Nick Mitchell, (appointed as the Co-Chief Operating Officer) an aggregate of 700,000 shares of the Company's common stock.\n\n## 11. Recent Developments\n\n**Major Acquisition Completed:**\n- ASP Isotopes Inc. (Nasdaq: ASPI) has successfully closed its previously announced acquisition of Renergen Limited, creating a combined company that is focused on the production of critical isotopes and helium. This strategic acquisition integrates ASP Isotopes' advanced enrichment technologies with Renergen's established helium and natural gas operations, positioning the combined company to address escalating demand in high-technology sectors.\n\n**Securities Litigation:**\n- On December 4, 2025, Judge McMahon granted in part and denied in part the defendants' motion to dismiss in the securities class action against ASP Isotopes Inc.. The Court dismissed claims regarding vague statements of optimism but allowed claims concerning the company's uranium enrichment capabilities to proceed.\n- On November 26, 2024, Fuzzy Panda Research published a report which alleged that ASP Isotopes is \"using old, disregarded laser enrichment technology to masquerade as a new, cutting-edge Uranium enrichment.\"\n\n**Capital Raises and Expansion:**\n- The Florida site currently offers SPECT; PET services are expected to start in 2027. The acquisition is described as accretive to 2026 revenues, EBITDA and EPS.\n\n## 12. AI Investment Rating & Fair Value Assessment\n\n**Analyst Ratings:**\n- According to 2 analysts, the average rating for ASPI stock is \"Strong Buy.\" The 12-month stock price target is $12.0, which is an increase of 60.86% from the latest price.\n- We've gathered analysts' opinions on ASP Isotopes Inc. future price: according to them, ASPI price has a max estimate of 15.00 USD and a min estimate of 11.00 USD.\n\n**Investment Considerations:**\n\n**Positives:**\n- Completed transformative Renergen acquisition providing access to $750M in debt funding\n- Strong revenue growth (857% in 2024)\n- Commercial production of multiple isotopes now underway\n- Strategic positioning in critical materials markets\n- Strong governmental backing through DFC funding\n\n**Risks:**\n- Ongoing securities litigation with mixed court rulings\n- Substantial losses despite revenue growth\n- High volatility and speculative nature\n- Execution risks on multiple concurrent projects\n\n**Buy Rating: 7.2/10**\n\nGiven the company's positioning in critical materials markets, recent completion of the Renergen acquisition, strong analyst sentiment, and access to substantial non-dilutive funding, the stock presents strong growth potential. However, ongoing litigation, execution risks, and the early-stage nature of the business warrant caution. The fair value estimate is approximately **$11.50-$13.00** based on analyst targets and the company's strategic positioning, suggesting potential upside from current levels around $7.50.",
  "generated_date": "2026-01-13T18:02:14.115282",
  "next_refresh_date": "2026-04-14T18:02:14.115282",
  "model": "claude-sonnet-4-20250514",
  "cost": 0.36158205,
  "tokens": {
    "input": 190,
    "output": 3924,
    "cache_creation": 64153,
    "cache_read": 205261
  }
}